Katie Wright, Author at European Medical Journal - Page 6 of 45

EADV 2025: Adults With AD Show Higher Cardiovascular Risk

The results revealed that patients with AD displayed a less favourable cardiovascular risk profile.

EADV 2025: Sleep Apnoea Linked to Increased Skin Disorders

Beyond disease associations, CPAP mask-related skin complications such as dermatitis may arise due to friction, pressure, moisture, or sensitivity to mask materials.

EADV 2025: Delays in AD Treatment Differ Across UK

A key finding was that patients treated at specialist centres experienced a significantly shorter delay in switching from immunosuppressants to advanced systemic therapies.

EADV 2025: Smoking Linked to Greater Severity in HS

In Cohort 1, data from 787 participants revealed that current smokers, who comprised 53.9% of the group, were more likely to present with severe disease.

Immune Genes Driving MAFLD Progression and Diagnosis Revealed

Emerging evidence points to the role of CD4+ T cell subsets in fuelling MAFLD-related inflammation and fibrosis.

LSD-Based Treatment Achieves Rapid Anxiety Relief in Clinical Trial

Single-dose MM120 provides fast, lasting anxiety relief in generalised anxiety disorder, paving the way for new treatments.

Three-Month Clofazimine Regimen Fails to Shorten Tuberculosis Treatment

A 3-month clofazimine- and rifapentine-containing regimen for drug-susceptible TB failed to improve cure rates and caused more severe adverse events than standard therapy, according to the Clo-Fast trial.

Combined Tofacitinib and UVB Therapy Shows Promise in Vitiligo

Ultraviolet B (UVB) phototherapy is the traditional non-pharmacological approach, promoting repigmentation by stimulating melanin production.

Can a New Biomarker Improve Bladder Cancer Detection?

With limited early-detection tools and only modest improvements in survival for advanced disease, clinicians urgently need reliable biomarkers to improve prognostication.

Reducing Hidden Costs of Childhood Food Allergy Management

A recent mixed-methods study evaluated NOURISH-US, a revised food-supplement programme designed to ease costs for households with a child aged 12 or younger managing any food allergy.